Healthcare Providers’ and Pregnant People’s Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus
Authors:
- Kathleen M. BeusterienKBKathleen M. Beusterien
- Amy W. LawALAmy W. Law
- Martine C. MaculaitisMMMartine C. Maculaitis
- Oliver WillOWOliver Will
- Lewis KopenhaferLKLewis Kopenhafer
- Patrick OlsenPOPatrick Olsen
- Brett HauberBHBrett Hauber
- Jeffrey T. VietriJVJeffrey T. Vietri
- Joseph C. CappelleriJCJoseph C. Cappelleri
- Joshua R. CoulterJCJoshua R. Coulter
- Kimberly M. SheaKSKimberly M. Shea
Open Access
Abstract
We assessed the impact of respiratory syncytial virus (RSV) preventive characteristics on the intentions of pregnant people and healthcare providers (HCPs) to protect infants with a maternal vaccine or monoclonal antibodies (mAbs). Pregnant people and HCPs who treated pregnant people and/or infants were recruited via convenience sample from a general research panel to complete a cross-sectional, web-based survey, including a discrete choice experiment (DCE) wherein respondents chose between hypothetical RSV preventive profiles varying on five attributes (effectiveness, preventive type [maternal vaccine vs. mAb], injection recipient/timing, type of medical visit required to receive the injection, and duration of protection during RSV season) and a no-preventive option. A best–worst scaling (BWS) exercise was included to explore the impact of additional attributes on preventive preferences. Data were collected between October and November 2022. Attribute-level preference weights and relative importance (RI) were estimated. Overall, 992 pregnant people and 310 HCPs participated. A preventive (vs. none) was chosen 89.2% (pregnant people) and 96.0% (HCPs) of the time (DCE). Effectiveness was most important to preventive choice for pregnant people (RI = 48.0%) and HCPs (RI = 41.7%); all else equal, pregnant people (RI = 5.5%) and HCPs (RI = 7.2%) preferred the maternal vaccine over mAbs, although preventive type had limited influence on choice. Longer protection, protection starting at birth or the beginning of RSV season, and use for both pre-term and full-term babies were ranked highest in importance (BWS). Pregnant people and HCPs strongly preferred a preventive to protect infants against RSV (vs. none), underscoring the need to incorporate RSV preventives into routine care.Keywords
Funding Information
- Pfizer Inc.
This publication has 32 references indexed in Scilit:
- Value profile for respiratory syncytial virus vaccines and monoclonal antibodiesVaccine, 2023
- A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task ForceValue in Health, 2023
- Maternal vaccination: a review of current evidence and recommendationsAmerican Journal of Obstetrics and Gynecology, 2021
- Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in ChildrenInfectious Diseases and Therapy, 2018
- How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validityThe European Journal of Health Economics, 2018
- The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early ChildhoodInfectious Diseases and Therapy, 2017
- Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task ForceValue in Health, 2016
- Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task ForceValue in Health, 2013
- Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task ForceValue in Health, 2011
- Best–worst scaling: What it can do for health care research and how to do itJournal of Health Economics, 2007